Kardigan Q2 2026: $116.2M net loss despite $660.7M cash cushion; $43.5M non-cash charge tied to milestone revaluation
KARD is trading near its 52-week low of $19.58 (4.2% above the low).
Summary
Kardigan's Q2 net loss reached $116.2 million, including a $43.5 million non-cash charge from milestone liability revaluation. Cash and investments stood at $660.7 million, funding operations through pivotal clinical data readouts anticipated in H1 2027.
Key Events · Earnings and Guidance · KARD
-
Q2 Net Loss of $116.2M
The net loss widened to $116.2 million from $57.4 million a year ago, driven by a $43.5 million non-cash charge from the change in fair value of contingent milestone liabilities, plus higher R&D spending as clinical trials advance.
-
$43.5M Non-Cash Milestone Liability Charge
This charge reflects a mark-to-market revaluation of contingent payments tied to Kardigan's stock price, not a cash outflow or new dilution. The liability increased because the post-IPO share price raised the probability of hitting valuation-based milestones.
-
Strong Cash Position of $660.7M
Cash, equivalents, and investments totaled $660.7 million at quarter-end, following the $422.4 million IPO. Management expects this to fund operations for at least 12 months and through key data readouts in H1 2027.
-
R&D Spending Rises 57% to $56.4M
R&D expenses increased to $56.4 million, driven by the ramp-up of the Danicamtiv Phase 2b/3 trial and higher headcount. Program expenses for Danicamtiv alone rose to $13.2 million from $0.9 million a year ago.
Analysis · KARD · Life Sciences
In its first quarterly filing as a public company, Kardigan posted a $116.2 million net loss. The primary driver was a $43.5 million non-cash charge from revaluing contingent milestone liabilities—a mark-to-market adjustment triggered by the post-IPO share price increase, not a cash outflow or new dilution. With $660.7 million in cash and investments at quarter-end, the company has a multi-year runway to advance its three lead cardiovascular drug candidates toward key data readouts expected in the first half of 2027.
At the time of this filing, KARD was trading at $20.41 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $2B. The 52-week trading range was $19.58 to $27.00. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.